Agenus reports 48% estimated three-year survival in recurrent ovarian cancer trial of botensilimab plus balstilimab

By Public Technologies
  • Agenus reported three-year follow-up results from its Phase 1b C-800-01 ovarian cancer cohort, presented at IGCS 2026 in Montréal.
  • Follow-up indicated durable survival in heavily pretreated recurrent ovarian cancer, including patients with platinum-resistant or refractory disease.
  • Some patients remained alive without ongoing therapy at the latest cut, supporting a potential long-lasting benefit in a subset of responders.
  • Safety profile remained consistent with prior experience, with no new safety signals or treatment-related deaths reported.
  • BOT and BAL remain investigational, with the update aimed at strengthening the case for broader development in hard-to-treat tumors.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261003256338) on October 03, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.